Oxford BioDynamics Plc OXBOF
0.00 USD 0.00 (+50.00%)
At closeNov 10, 2026, 4:00 PM EST
0.003 Day range 0.003
0.0014 52-week range 0.007
- YTD
- +114.29%
- 1 year
- -34.78%
News
proactiveinvestors.co.uk Oxford BioDynamics shares soar 33% after unveiling breakthrough blood test for Chronic Fatigue Syndrome Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) shares surged 33% on Wednesday after the company announced it had developed a highly accurate blood test to diagnose Chronic Fatigue Syndrome, a condition…
proactiveinvestors.co.uk Oxford BioDynamics unveils blood test for Chronic Fatigue Syndrome with 96% accuracy Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) has developed what it calls a “first-in-class” blood test to diagnose Chronic Fatigue Syndrome, a breakthrough that could help end years of uncertainty for…
proactiveinvestors.co.uk Oxford BioDynamics shares climb blood test findings Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) shares strengthened on Thursday, after the health diagnostics company reported that its EpiSwitch CiRT blood test was shown to influence clinical decisions…
proactiveinvestors.co.uk Oxford BioDynamics partners with Google Cloud - ICYMI Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) executive chairman Iain Ross talked with Proactive about the company's new partnership with Google Cloud, a move he described as a major growth catalyst…
proactiveinvestors.co.uk Oxford BioDynamics soars on new Google collab Oxford BioDynamics PLC (AIM:OBD) shares soared in early deals, as it unveiled a new collaboration with Google Cloud. In the project, they plan to develop and deploy Oxford BioDynamics' EpiSwitch…
proactiveinvestors.co.uk Oxford BioDynamics shares jump 66% after Pfizer validates blood-based cancer biomarker technology Oxford BioDynamics PLC (AIM:OBD) shares jumped 66% after Pfizer published data confirming the effectiveness of the company's EpiSwitch blood-based biomarkers in monitoring tumour status and treatment…
proactiveinvestors.co.uk Oxford BioDynamics shares jump on UK lab accreditation for flagship cancer test Shares in Oxford BioDynamics PLC (AIM:OBD) rose as much as 9% in early trading on Friday after the company announced that its Oxford-based facility has been accredited by the UK's national…
proactiveinvestors.co.uk Oxford BioDynamics slumps on warning of need for new funding Oxford BioDynamics PLC (AIM:OBD) shares tumbled over 37% on Monday as the precision medicine test developer warned new funding would be needed by early next year. Plans were announced for senior…
businesswire.com Oxford BioDynamics part of consortium shortlisted for Strategic Government Initiative to Improve Cancer Immunotherapy OXFORD, England--(BUSINESS WIRE)-- #EpiSwitch--Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of…
proactiveinvestors.com Oxford Biodynamics tumbles as results knock froth off recent gains Shares in Oxford BioDynamics PLC (AIM:OBD) tumbled 23% to 26p, wiping out gains made in the past week, after it published results that were in line with most expectations. The company, which has…